Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPP-ACP for Prevention of White Spot Lesions in Orthodontic Patients
NCT03187548Phase 1Unknown
- Sponsor
- Cairo University
- Start
- Jul 2017
- Primary completion
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Nanoparticles
01
Overview
Phase 1, randomised trial of casein phosphopeptide-amorphous calcium phosphate in White spot lesion (WSL) (2 arms), sponsored by Cairo University. Primary endpoints: Effect on enamel surface color at 3 months and Effect on enamel surface at 3 months. Status: unknown.
02
Drugs
casein phosphopeptide-amorphous calcium phosphate
03
Conditions
White spot lesion (WSL)
Beyond the preview
Go deeper on NCT03187548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187548.